Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5276254
Max Phase: Preclinical
Molecular Formula: C31H35N7O2
Molecular Weight: 537.67
Associated Items:
ID: ALA5276254
Max Phase: Preclinical
Molecular Formula: C31H35N7O2
Molecular Weight: 537.67
Associated Items:
Canonical SMILES: CNC(=O)CCCCC[C@H](NC(=O)CCc1c[nH]c2ccccc12)c1ncc(-c2ccc(-n3cccn3)cc2)[nH]1
Standard InChI: InChI=1S/C31H35N7O2/c1-32-29(39)11-4-2-3-10-27(36-30(40)17-14-23-20-33-26-9-6-5-8-25(23)26)31-34-21-28(37-31)22-12-15-24(16-13-22)38-19-7-18-35-38/h5-9,12-13,15-16,18-21,27,33H,2-4,10-11,14,17H2,1H3,(H,32,39)(H,34,37)(H,36,40)/t27-/m0/s1
Standard InChI Key: CXGCPFUYZATRCE-MHZLTWQESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 537.67 | Molecular Weight (Monoisotopic): 537.2852 | AlogP: 5.23 | #Rotatable Bonds: 13 |
Polar Surface Area: 120.49 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 4 |
#RO5 Violations: 2 | HBA (Lipinski): 9 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.57 | CX Basic pKa: 5.86 | CX LogP: 3.87 | CX LogD: 3.86 |
Aromatic Rings: 5 | Heavy Atoms: 40 | QED Weighted: 0.15 | Np Likeness Score: -1.19 |
1. Bresciani A, Ontoria JM, Biancofiore I, Cellucci A, Ciammaichella A, Di Marco A, Ferrigno F, Francone A, Malancona S, Monteagudo E, Nizi E, Pace P, Ponzi S, Rossetti I, Veneziano M, Summa V, Harper S.. (2019) Improved Selective Class I HDAC and Novel Selective HDAC3 Inhibitors: Beyond Hydroxamic Acids and Benzamides., 10 (4): [PMID:30996783] [10.1021/acsmedchemlett.8b00517] |
Source(1):